Home Antibody All anti-STK17B antibodies
Also for STK17B (NM_004226)
|DRAK2 antibody was raised against a peptide corresponding to amino acids 351 to 365 of human DRAK2.|
||ELISA, WB, ICC: 10 ug/ml
|PBS containing 0.02% sodium azide.|
|Ion exchange chromatography purified
|Homo sapiens serine/threonine kinase 17b (STK17B)|
|Apoptosis is mediated by death domain containing adapter molecules and a caspase family of proteases. Certain serine/threonine protein kinases, such as ASK-1 and RIP, are mediators of apoptosis. Two novel serine/threonine kinases that induce apoptosis were recently identified and designated DRAK1 and DRAK2 (for DAP kinase-related apoptosis-inducing protein kinases) (1). DRAKs contain an N-terminal kinase domain and a C-terminal regulation domain. Overexpression of DRAK2 induces apoptosis. DRAKs have high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases, which mediates apoptosis through their catalytic activities. DRAK2 is located in nucleus and the messenger RNA was ubiquitously expressed in human tissues (1).|
* Availability is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
Western blot analysis of DRAK2 in Jurkat (1,3) and Raji (2,4) cell lysate in the absence (1,2) or presence (3,4) of blocking peptide with DRAK2 antibody at 1:500 dilution.
Immunocytochemistry of DRAK2 in Jurkat cells with DRAK2 antibody at 10 ug/mL.